---
layout: default
title: Amanita Muscaria Fruiting Body Anemone Pulsatilla 
parent: 僅模型預測 (L5)
nav_order: 305
evidence_level: L5
indication_count: 0
---

# Amanita Muscaria Fruiting Body Anemone Pulsatilla 
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Complex (27 Components): Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This product is a 27-ingredient homeopathic combination comprising classical homeopathic substances including Amanita muscaria, Arsenic trioxide, Mercury, Conium maculatum, and others—all prepared at homeopathic ultra-dilutions. The TxGNN model did **not generate any repurposing prediction** for this compound, as the combination could not be matched to a single DrugBank entity. With **no registered clinical trials, no mapped literature, and no US market authorizations**, evaluation at this stage is not feasible.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record |
| Predicted New Indication | No TxGNN prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 — No prediction, no supporting studies |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN repurposing prediction was generated for this product. The pipeline could not map the 27-component homeopathic mixture to a DrugBank entity, which is a prerequisite for knowledge-graph and deep-learning scoring.

From a pharmacological standpoint, this product contains substances that individually carry known biological activities at clinical doses—for example, arsenic trioxide (Trisenox®) is an FDA-approved antineoplastic agent for acute promyelocytic leukaemia, berberine (from *Berberis aquifolium*) has documented antimicrobial and metabolic effects, and goldenseal (*Hydrastis canadensis*) contains isoquinoline alkaloids. However, in a homeopathic preparation these substances are present at ultra-high dilutions (typically 6C–30C or higher), meaning the active moiety is considered absent or sub-pharmacological by conventional pharmacokinetic standards.

Because the product is an undefined mixture with no single INN, no DrugBank ID, and no regulatory approval in any queried jurisdiction, the repurposing evaluation framework cannot proceed through its standard pipeline. A meaningful mechanistic or clinical analysis would require decomposing the combination into individual active constituents and evaluating each separately.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

This product has no recorded authorizations in the queried database. No NDA, BLA, or OTC monograph record was returned.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note for reviewers**: Several individual ingredients in this combination are inherently hazardous at non-homeopathic doses—including arsenic trioxide (systemic toxin / antineoplastic), mercury (heavy-metal neurotoxin), conium maculatum (hemlock alkaloids), and lytta vesicatoria (cantharidin vesicant). Although homeopathic dilutions are intended to render these substances pharmacologically inert, handling, storage, and labelling obligations under relevant jurisdictional regulations (e.g., FDA OTC Homeopathic Policy 2019; CPG 400.400) should be confirmed before any further development steps.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline produced no repurposing prediction because the 27-ingredient homeopathic mixture cannot be resolved to a single DrugBank node. Combined with zero regulatory approvals, absent safety dossier, and no supporting clinical or preclinical literature, there is no evidentiary basis on which to advance this candidate.

**To proceed, the following is needed:**

- **Decompose the combination**: Identify which single active constituent (if any) is the intended pharmacological driver and submit that INN individually to the TxGNN pipeline.
- **Resolve DrugBank identity**: Obtain a DrugBank ID for the primary active ingredient(s) to enable KG-based repurposing scoring.
- **Clarify product category**: Determine whether this product is intended as a homeopathic OTC remedy or as a pharmaceutical combination; the regulatory pathway and evidence standard differ fundamentally.
- **Safety dossier retrieval**: Download and parse the product's package insert (if available in any jurisdiction) to populate key warnings, contraindications, and drug interaction data.
- **Define original indication**: Establish the product's claimed therapeutic use before any repurposing hypothesis can be framed.
- **Consider individual-component analysis**: If the goal is to explore repurposing signals within this ingredient set (e.g., arsenic trioxide for APL extension, berberine for metabolic disease), each component should be evaluated as a separate candidate with its own Evidence Pack.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

